Regulations of Free Fatty Acids and Diabetic Parameters in Drug Naïve Subjects with Type 2 Diabetes Treated with Canagliflozin Monotherapy

Abstract

The objective of this study is to investigate the regulations of FFA with canagliflozin in relation to metabolic parameters. Drug naïve subjects with T2DM were administered 50–100 mg/day canagliflozin monotherapy (n=70) for 3 months. Significant correlations between the changes of (Δ) FFA and Δadipo-IR (R=0.496), but no correlations between ΔFFA and ΔHOMA-R were observed. The subjects were divided into three groups with similar numbers according to Δ FFA: group A: highest tertile: (ΔFFA=38.7%, n=23); group B: intermediate tertile: (ΔFFA=2%, n=23); group C: lowest tertile: (ΔFFA=−36%, n=24). Metabolic parameters were compared between group A and group C. At baseline, FFA was higher in group C than group A (p<0.002). Greater degrees of HbA1c reduction and increases of insulin were observed in group C than group A (both p<0.05). In group A, significant reductions of BMI (−2.6%) and HOMA-R (−30%) were seen. In group C, significant reductions of non-HDL-C (−6.2%), UA (−7.6%) or adipo-IR (−28.7%), and increases of HOMA-B (+85.6%) were observed. Taken together, 1) certain population treated with canagliflozin showed decreased FFA. 2) beta-cell function increased while atherogenic cholesterol, UA and adipo-IR decreased in those with reduced FFA. Better glycemic efficacies were seen in these populations. 3) body weight and whole body insulin resistance (HOMA-R) significantly decreased in those with elevated FFA. 4) FFA is linked to adipose insulin resistance (adipo-IR), while it does not appear to impact whole body insulin resistance (HOMA-R).

Key words

canagliflozin/SGLT-2 inhibitor - free fatty acid - insulin resistance - beta-cell function

Publication History

Received: 17 July 2021

Accepted: 29 August 2021

Article published online:
02 November 2021

• References

• 1 Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011; 32: 515-531
• 2 Whalen K, Miller S, Onge ES. The role of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes. Clin Ther 2015; 37: 1150-1166
• 3 Patoulias D, Imprialos K, Stavropoulos K. et al. SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature. Curr Clin Pharmacol 2018; 13: 261-272
• 4 Patel K, Carbone A. Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data. Ann Pharmacother 2019; 53: 1227-1237
• 5 Kuriyama C, Ueta K, Arakawa K. Pharmacological and clinical profile of a novel SGLT2 inhibitor canagliflozin hydrate (CANAGLU) Nihon Yakurigaku Zasshi 2015; 146: 332-341
• 6 Rosenthal N, Meininger G, Ways K. et al. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci 2015; 1358: 28-43
• 7 Polidori D, Iijima H, Goda M. et al. Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin. Diabetes Obes Metab 2018; 20: 1321-1326
• 8 Melmer A, Kempf P, Lunger L. et al. Short-term effects of dapagliflozin on insulin sensitivity, postprandial glucose excursion and ketogenesis in type 1 diabetes mellitus: A randomized, placebo-controlled, double blind, cross-over pilot study. Diabetes Obes Metab 2018; 20: 2685-2689
• 9 Merovci A, Abdul-Ghani M, Mari A. et al. Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males. J Clin Endocrinol Metab 2016; 101: 1249-1256
• 10 Takasu T, Takakura S. Protective Effect of Ipragliflozin on Pancreatic Islet Cells in Obese Type 2 Diabetic db/db Mice. Biol Pharm Bull 2018; 41: 761-769
• 11 Kutoh E, Wada A, Murayama T. et al. Characterization of Metabolic Parameters in Responders and Nonresponders Treated with Canagliflozin Monotherapy in Drug-naive Subjects with Type 2 Diabetes. Indian J Endocrinol Metab 2018; 22: 185-190
• 12 Kutoh E, Wada A, Murayama T. et al. Two Glucose-Lowering Mechanisms of Canagliflozin Depending on Body Weight Changes in Drug-Naïve Subjects with Type 2 Diabetes. Drugs R D 2018; 18: 309-315
• 13 I S Sobczak A, A Blindauer C, J Stewart A Changes in Plasma Free Fatty Acids Associated with Type-2 Diabetes. Nutrients. 2019 11. 2022
• 14 Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002; 32: 14-23
• 15 Bergman RN, Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 2000; 11: 351-356
• 16 DeFronzo RA. Dysfunctional fat cells, lipotoxicity and type 2 diabetes. Int J Clin Pract Suppl 2004; 9-21
• 17 Michot C, Mamoune A, Vamecq J. et al. Combination of lipid metabolism alterations and their sensitivity to inflammatory cytokines in human lipin-1-deficient myoblasts. Biochim Biophys Acta 2013; 1832: 2103-2114
• 18 Adachi T, Tanaka T, Takemoto K. et al. Free fatty acids administered into the colon promote the secretion of glucagon-like peptide-1 and insulin. Biochem Biophys Res Commun 2006; 340: 332-337
• 19 Gastaldelli A, Gaggini M, DeFronzo RA. Role of Adipose Tissue Insulin Resistance in the Natural History of Type 2 Diabetes: Results From the San Antonio Metabolism Study. Diabetes 2017; 66: 815-822
• 20 Matthews DR, Hosker JP, Rudenski AS. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
• 21 Bland JM, Altman DG. Regression towards the mean. BMJ 1994; 308: 1499
• 22 Leyva F, Wingrove CS, Godsland IF. et al. The glycolytic pathway to coronary heart disease: a hypothesis. Metabolism 1998; 47: 657-662
• 23 Neal B, Perkovic V, Mahaffey KW. et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377: 644-657
• 24 Guthrie R. Canagliflozin and cardiovascular and renal events in type 2 diabetes. Postgrad Med 2018; 130: 149-153